Compare Bristol-Myers Squibb Co (BMY) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs ProShares UltraPro QQQ ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while ProShares UltraPro QQQ ETF trades at $74.74. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while ProShares UltraPro QQQ ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| BMY | TQQQ | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $87.22 |
52-Week Low | $42.60 | $37.89 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
TQQQ trades at $74.61, up 1.12% with a bullish technical signal from moving averages. The leveraged ETF benefits from strong Nasdaq-100 performance and AI-driven tech momentum. Recent institutional buying by Bay Colony Advisory Group and positive earnings from hyperscalers support current levels. However, the RSI at 74 suggests potential overbought conditions near key resistance at $75.
Outlook remains positive given tech sector strength, but volatility decay and leverage risks require careful position sizing. The ETF's structural costs compound daily, making it better suited for tactical rather than long-term holdings. Current momentum favors continued upside if tech earnings maintain strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
